AFFiRiS raises €10M; FDA clears IND applications for BiondVax flu vax and Genticel HPV jab;

> AFFiRiS raised €10 million in a financing round. The funding will be used to advance its AFFITOME technology for the prevention and therapy of chronic illnesses, including Parkinson's disease. Release

> BiondVax ($BVXV) announced that its Investigational New Drug Application for its universal flu vaccine candidate was accepted by the FDA. News

> Genticel announced that the FDA has cleared its IND to conduct a Phase I study of its HPV candidate. Release

> France-based Biosantech announced that its HIV vaccine candidate is safe and not toxic for patients. The results are based on a study involving 48 HIV-positive patients. More

> The American Medical Association seeks to put an end to exemptions to immunizations that are not for medical reasons. Story

> The Defense Threat Reduction Agency is investing $5.2 million in EpiVax for the development of a new vaccine against Q fever. Release

Suggested Articles

After countless headlines from a Dengvaxia safety scandal in the Philippines, officials are now considering using the Sanofi vaccine again.

Merck's oncology superstar Keytruda has been stealing the spotlight, but in vaccines, the drugmaker has growth figures to tout.

Experts are pushing for the introduction of J&J's vaccine in the response to the Ebola outbreak in the Democratic Republic of Congo.